Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers.

Study Objective: To determine whether the pharmacokinetics of atazanavir, a protease inhibitor used to treat human immunodeficiency virus (HIV) infection, are altered by its coadministration with lansoprazole, a proton pump inhibitor.

Design: Single-dose, open-label, complete-crossover study.

Setting: Clinical research center.